Press Releases

MGEN $5.61 $ + 0.02 (0.36%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
2/8/2018
6:45 PM ET
Press Release

miRagen Therapeutics, Inc. Prices Public Offering of Common Stock

2/8/2018

BOULDER, Colo., Feb. 08, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
2/5/2018
6:05 AM ET
Press Release

miRagen Therapeutics Announces Proposed Public Offering of Common Stock

2/5/2018

BOULDER, Colo., Feb. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
2/2/2018
7:00 AM ET
Press Release

miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum

2/2/2018

90% of evaluable patients show clinical improvement in the ongoing Phase 1 clinical trial of MRG-106.80% of patients treated with 300 mg IV infusion, the anticipated Phase 2 clinical trial dose, demon...

 Continue Reading
1/24/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum

1/24/2018

BOULDER, Colo., Jan. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
1/5/2018
7:00 AM ET
Press Release

miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris

1/5/2018

BOULDER, Colo., Jan. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
Displaying 1 to 5 (of 40 releases)